Literature DB >> 2033916

[Human anti-murine immunoglobulin antibodies as disturbing factors in TSH determination].

G Horneff1, W Becker, F Wolf, J R Kalden, G R Burmester.   

Abstract

Monoclonal murine antibodies are increasingly used for immunotherapy and in vivo diagnostic procedures such as immunoscintigraphy. The therapeutic or diagnostic reagent however, is a foreign antigen, which may induce host reactivity. This may interfere with the therapeutic or diagnostic reagent in vivo, resulting in a loss of efficacy or the necessity to increase dosages. In addition, there is an important interference to in vitro immunoassays detecting specific antigens utilizing murine monoclonal antibodies. In the present study, sera of patients who had undergone a therapeutic trial using 140 mg of an anti-CD4 antibody, were investigated. Human anti-murine-immunoglobulin-antibodies (HAMA) were detected 2-3 weeks after treatment was started and reached maximal amounts of 0.8 micrograms/ml after a single and 2 micrograms/ml after a repeated treatment course. Parallely raised values of TSH were found in sera containing HAMAs of more than 0.3 micrograms/ml. Elevations of TSH levels up to 13 microU/ml were most pronounced after a repeated trial of the murine antibody and were detectable up to 20 weeks.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033916     DOI: 10.1007/bf01646945

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  10 in total

Review 1.  [The TSH, TRH test].

Authors:  A Von zur Mühlen; G Brabant
Journal:  Internist (Berl)       Date:  1988-08       Impact factor: 0.743

2.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

3.  Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis.

Authors:  G Horneff; T Winkler; J R Kalden; F Emmrich; G R Burmester
Journal:  Clin Immunol Immunopathol       Date:  1991-04

4.  Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies.

Authors:  W Becker; F Emmrich; G Horneff; G Burmester; F Seiler; A Schwarz; J Kalden; F Wolf
Journal:  Eur J Nucl Med       Date:  1990

5.  Immunosuppression with monoclonal antibodies in multiple sclerosis.

Authors:  D A Hafler; H L Weiner
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

6.  A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants.

Authors: 
Journal:  N Engl J Med       Date:  1985-08-08       Impact factor: 91.245

7.  "Sandwich"-type immunoassay of carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy.

Authors:  F J Primus; E A Kelley; H J Hansen; D M Goldenberg
Journal:  Clin Chem       Date:  1988-02       Impact factor: 8.327

8.  Kinetic data of in-vivo labeled granulocytes in humans with a murine Tc-99m-labelled monoclonal antibody.

Authors:  W Becker; U Borst; W Fischbach; B Pasurka; R Schäfer; W Börner
Journal:  Eur J Nucl Med       Date:  1989

9.  Interference by anti-immunoglobulin G antibodies in immunoradiometric assays of thyrotropin involving mouse monoclonal antibodies.

Authors:  M H Zweig; G Csako; C C Benson; B D Weintraub; B B Kahn
Journal:  Clin Chem       Date:  1987-06       Impact factor: 8.327

10.  Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.

Authors:  G Horneff; G R Burmester; F Emmrich; J R Kalden
Journal:  Arthritis Rheum       Date:  1991-02
  10 in total
  1 in total

1.  Expression of recombinant antibodies.

Authors:  André Frenzel; Michael Hust; Thomas Schirrmann
Journal:  Front Immunol       Date:  2013-07-29       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.